Announced
Lyell Immunopharma to acquire ImmPACT for $87m.
Synopsis
Lyell Immunopharma, a fully integrated company developing next-generation T-cell reprogramming technologies, agreed to acquire ImmPACT, a privately-owned clinical-stage biotechnology company, for $87m. “Lyell’s vision is to bring meaningful and durable clinical benefit to patients suffering from cancer with our next-generation cell therapies,” Lynn Seely, Lyell President and CEO.
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
Bidder Team (11)
By continuing, you agree to our Terms & Conditions and our Data Privacy Policy
All rights reserved. Copyright © 2025 Datasite